ATP-binding cassette transporters in inflammatory brain disease

Current Pharmaceutical Design

Volumn 17, Issue 26, 2011, Pages 2803-2807

  Chan, A ^a   Gold, R ^a   von Ahsen, N ^b  

^a ST JOSEF HOSPITAL   (Germany)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

Experimental autoimmune encephalomyelitis; HIV associated neurocognitive disorders; Mitoxantrone; Multiple sclerosis

Indexed keywords

ABC TRANSPORTER; ANTIVIRUS AGENT; BREAST CANCER RESISTANCE PROTEIN; GLUCOCORTICOID; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1;

ALLERGIC ENCEPHALOMYELITIS; ARTICLE; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM DISEASE; COGNITIVE DEFECT; DRUG FATALITY; DRUG PENETRATION; ENCEPHALITIS; GENETIC VARIABILITY; GONAD DYSFUNCTION; HEART VENTRICLE FAILURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKEMIA; MULTIPLE SCLEROSIS; NONHUMAN; PATHOGENESIS; PHARMACOGENETICS; PRIORITY JOURNAL; REGULATORY MECHANISM; TREATMENT RESPONSE;

EID: 80053503165     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211797440131     Document Type: Article

References (48)

1. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein. J Histochem Cytochem 1989; 37: 159-64.
2. Roberts DJ, Goralski KB. A critical overview of the influence of inflammation and infection on P-glycoprotein expression and activity in the brain. Expert Opin Drug Metab Toxicol 2008; 4: 1245-64.
3. Frank MH, Denton MD, Alexander SI, Khoury SJ, Sayegh MH, Briscoe DM. Specific MDR1 P-glycoprotein blockade inhibits human alloimmune T cell activation in vitro. J Immunol 2001; 166: 2451-9.
4. Cotte S, von Ahsen N, Kruse N, et al. ABC-transporter genepolymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis. Brain 2009; 132: 2517-30.
5. Drach J, Gsur A, Hamilton G, et al. Involvement of P-glycoprotein in the transmembrane transport of interleukin-2 (IL-2), IL-4, and interferon-gamma in normal human T lymphocytes. Blood 1996; 88: 1747-54.
6. Raggers RJ, Vogels I, van Meer G. Multidrug-resistance Pglycoprotein (MDR1) secretes platelet-activating factor. Biochem J 2001; 357: 859-65.
7. Kooij G, Mizee MR, van Horssen J, et al. Adenosine triphosphatebinding cassette transporters mediate chemokine (C-C motif) ligand 2 secretion from reactive astrocytes: relevance to multiple sclerosis pathogenesis. Brain 2011; 134: 555-70.
8. Goralski KB, Hartmann G, Piquette-Miller M, Renton KW. Down regulation of mdr1a expression in the brain and liver during CNS inflammation alters the in vivo disposition of digoxin. Br J Pharmacol 2003; 139: 35-48.
9. Hartz AM, Bauer B, Fricker G, Miller DS. Rapid regulation of Pglycoprotein at the blood-brain barrier by endothelin-1. Mol Pharmacol 2004; 66: 387-94.
10. Hartz AM, Bauer B, Fricker G, Miller DS. Rapid modulation of Pglycoprotein- mediated transport at the blood-brain barrier by tumor necrosis factor-alpha and lipopolysaccharide. Mol Pharmacol 2006; 69: 462-70.
11. Bauer B, Hartz AM, Miller DS. Tumor necrosis factor alpha and endothelin-1 increase P-glycoprotein expression and transport activity at the blood-brain barrier. Mol Pharmacol 2007; 71: 667-75.
12. Heaton RK, Clifford DB, Franklin DR, Jr., et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 2010; 75: 2087-96.
13. Gonzalez-Scarano F, Martin-Garcia J. The neuropathogenesis of AIDS. Nat Rev Immunol 2005; 5: 69-81.
14. Loscher W, Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci 2005; 6: 591-602.
15. Ronaldson PT, Lee G, Dallas S, Bendayan R. Involvement of Pglycoprotein in the transport of saquinavir and indinavir in rat brain microvessel endothelial and microglia cell lines. Pharm Res 2004; 21: 811-8.
16. Strazielle N, Ghersi-Egea JF. Factors affecting delivery of antiviral drugs to the brain. Rev Med Virol 2005; 15: 105-33.
17. Bilello JA, Bilello PA, Stellrecht K, et al. Human serum alpha 1 acid glycoprotein reduces uptake, intracellular concentration, and antiviral activity of A-80987, an inhibitor of the human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother 1996; 40: 1491-7.
18. Washington CB, Wiltshire HR, Man M, et al. The disposition of saquinavir in normal and P-glycoprotein deficient mice, rats, and in cultured cells. Drug Metab Dispos 2000; 28: 1058-62.
19. Huisman MT, Smit JW, Wiltshire HR, Hoetelmans RM, Beijnen JH, Schinkel AH. P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir. Mol Pharmacol 2001; 59: 806-13.
20. Park S, Sinko PJ. P-glycoprotein and mutlidrug resistanceassociated proteins limit the brain uptake of saquinavir in mice. J Pharmacol Exp Ther 2005; 312: 1249-56.
21. Ronaldson PT, Persidsky Y, Bendayan R. Regulation of ABC membrane transporters in glial cells: relevance to the pharmacotherapy of brain HIV-1 infection. Glia 2008; 56: 1711-35.
22. Langford D, Grigorian A, Hurford R, et al. Altered P-glycoprotein expression in AIDS patients with HIV encephalitis. J Neuropathol Exp Neurol 2004; 63: 1038-47.
23. Choo EF, Leake B, Wandel C, et al. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos 2000; 28: 655-60.
24. Khaliq Y, Gallicano K, Venance S, Kravcik S, Cameron DW. Effect of ketoconazole on ritonavir and saquinavir concentrations in plasma and cerebrospinal fluid from patients infected with human immunodeficiency virus. Clin Pharmacol Ther 2000; 68: 637-46.
25. van Praag RM, Weverling GJ, Portegies P, et al. Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir. AIDS 2000; 14: 1187-94.
26. Zastre JA, Chan GN, Ronaldson PT, et al. Up-regulation of Pglycoprotein by HIV protease inhibitors in a human brain microvessel endothelial cell line. J Neurosci Res 2009; 87: 1023-36.
27. Haas DW, Johnson B, Nicotera J, et al. Effects of ritonavir on indinavir pharmacokinetics in cerebrospinal fluid and plasma. Antimicrob Agents Chemother 2003; 47: 2131-7.
28. Fellay J, Marzolini C, Meaden ER, et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 2002; 359: 30-6.
29. van Waterschoot RA, ter Heine R, Wagenaar E, et al. Effects of cytochrome P450 3A (CYP3A) and the drug transporters Pglycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir. Br J Pharmacol 2010; 160: 1224-33.
30. Kaddoumi A, Choi SU, Kinman L, et al. Inhibition of Pglycoprotein activity at the primate blood-brain barrier increases the distribution of nelfinavir into the brain but not into the cerebrospinal fluid. Drug Metab Dispos 2007; 35: 1459-62.
31. Eyal S, Hsiao P, Unadkat JD. Drug interactions at the blood-brain barrier: fact or fantasy? Pharmacol Ther 2009; 123: 80-104.
32. Mallipeddi R, Rohan LC. Progress in antiretroviral drug delivery using nanotechnology. Int J Nanomedicine 2010; 5:533-47.: 533-47.
33. Shaik N, Pan G, Elmquist WF. Interactions of pluronic block copolymers on P-gp efflux activity: experience with HIV-1 protease inhibitors. J Pharm Sci 2008; 97: 5421-33.
34. Spitzenberger TJ, Heilman D, Diekmann C, et al. Novel delivery system enhances efficacy of antiretroviral therapy in animal model for HIV-1 encephalitis. J Cereb Blood Flow Metab 2007; 27: 1033-42.
35. Compston A, Coles A. Multiple sclerosis. Lancet 2008; 372: 1502-17.
36. McFarland HF, Martin R. Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol 2007; 8: 913-9.
37. Gold R, Linington C, Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 2006; 129: 1953-71.
38. Kooij G, Backer R, Koning JJ, et al. P-glycoprotein acts as an immunomodulator during neuroinflammation. PLoS One 2009; 4: e8212.
39. Kooij G, van Horssen J., de Lange EC, et al. T lymphocytes impair P-glycoprotein function during neuroinflammation. J Autoimmun 2010; 34: 416-25.
40. Mauch E, Kornhuber HH, Krapf H, Fetzer U, Laufen H. Treatment of multiple sclerosis with mitoxantrone. Eur Arch Psychiatry Clin Neurosci 1992; 242: 96-102.
41. Morrissey SP, Le PE, Edan G. Mitoxantrone in the treatment of multiple sclerosis. Int MS J 2005; 12: 74-87.
42. Wiendl H, Toyka KV, Rieckmann P, Gold R, Hartung HP, Hohlfeld R. Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol 2008; 255: 1449-63.
43. Chan A, Weilbach FX, Toyka KV, Gold R. Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients. Clin Exp Immunol 2005; 139: 152-8.
44. Robey RW, Polgar O, Deeken J, To KW, Bates SE. ABCG2: determining its relevance in clinical drug resistance. Cancer Metastasis Rev 2007; 26: 39-57.
45. Dörr J, Bitsch A, Schmailzl KJ, et al. Severe cardiac failure in a patient with multiple sclerosis following low-dose mitoxantrone treatment. Neurology 2009; 73: 991-3.
46. Zhou S, Zong Y, Lu T, Sorrentino BP. Hematopoietic cells from mice that are deficient in both Bcrp1/Abcg2 and Mdr1a/1b develop normally but are sensitized to mitoxantrone. Biotechniques 2003; 35: 1248-52.
47. Edan G, Miller D, Clanet M, et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 1997; 62: 112-8.
48. Pavek P, Merino G, Wagenaar E, et al. Human breast cancer resistance protein: interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and transport of cimetidine. J Pharmacol Exp Ther 2005; 312: 144-52.